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Abstract
Introduction: Previous studies have shown that obese individuals have reduced
natriuretic peptide levels. But conflicting data exist on the relation of natriuretic
peptide levels to other metabolic risk factors. 
Material and methods: We investigated the relationship between plasma N-terminal
pro-B-type natriuretic peptide levels (NT-proBNP) and metabolic syndrome (MetS)
and metabolic risk factors in 469 patients free of heart failure. Two hundred thirty
diagnosed MetS cases and 239 non-MetS cases were included in this study.
Echocardiography examinations were performed and left ventricular mass index
was calculated according to the Devereux correction formula. NT-proBNP was
measured by electro  chemi  luminescence. The log-transformed NT-proBNP levels
were used for abnormal distribution. Multiple linear regression analysis was
performed to assess the association between levels of NT-proBNP and metabolic
factors. Covariance analysis was used for group comparisons. 
Results: Log NT-proBNP levels were independently related to age, gender, body
mass index, systolic blood pressure, diastolic blood pressure, fasting blood
glucose, triglyceride, high density lipoprotein cholesterol, low density lipoprotein
cholesterol, left ventricular mass index and left ventricular ejection fraction in
multiple linear regression analysis (p < 0.05). Adjusted log NT-proBNP levels
were lower in persons with MetS compared with those without MetS (p < 0.05).
Individuals with hyperlipidaemia, elevated body mass index, diastolic blood
pressure and fasting plasma glucose had lower levels of log NT-proBNP than
those without MetS (p < 0.05). 
Conclusions: There is a relationship between metabolic components and lower
plasma NT-proBNP concentration. These findings raise the possibility that
reduced plasma NT-proBNP levels are a manifestation of MetS, which might
possess significant clinical and pathophysiological implications.
Key words: natriuretic peptide, hyperlipidaemia, left ventricular mass index, risk
factors.
Introduction
The metabolic syndrome (MetS) is a worldwide problem, which refers
to a constellation of coronary heart disease (CHD) risk factors including
obesity and abdominal fat distribution, disorders of glucose and lipid
metabolism, and hypertension. The burden of MetS is likely to continue
to rise, largely due to decreased physical activity and increases in obesity
in our society. 
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Obesity is associated with depressed N-terminal
pro-B-type natriuretic peptide (NT-proBNP), a cardiac
hormone that was recognized as a new and useful
biochemical marker for both diagnosis and ruling
out of congestive heart failure [1]. Despite the well-
documented association between NT-proBNP levels
and obesity, data on relations with other metabolic
risk factors are mixed [2, 3]. Other studies have not
found an association between plasma natriuretic
peptide levels and hyper  lipidaemia [4] or hyper  -
glycaemia [5]. However, Olsen et al. [6] reported an
inverse association between NT-proBNP levels and
plasma lipids and glucose. 
Thus, we sought to elucidate the relations
between plasma NT-proBNP levels and metabolic
risk factors and the metabolic syndrome in
a Chinese study. We hypothesized that plasma 
NT-proBNP levels would be lower in the presence
of the metabolic syndrome or its components. 
Material and methods
Study population
We retrospectively evaluated the 250 MetS
patients and 250 non-MetS cases who were admitted
to the department of endocrinology of Huashan
Hospital affiliated to Fudan University from July 2005
to August 2009. Participants were excluded for the
following reasons: unavailable NT-proBNP levels 
(n = 20), hepatic (total bilirubin level > 5 mg/dl; 
n = 0) or renal insufficiency (creatinine > 2.0 mg/dl;
n = 13), a history of heart failure (n = 11), and missing
covariates (n = 3). After these exclusions, 469 subjects
(94% of attendees) remained eligible. Written consent
was obtained from all patients before the study.
Measurements 
The subjects were interviewed for the do  -
cumentation of medical histories (hypertension 
and diabetes) and medication, history of smoking
habits (current, former or never), laboratory
assessment of cardiovascular disease risk factors, and
standardized echocardiographic examination. The
body weight of the subjects, wearing light clothing
and without their shoes on, was measured with 0.1 kg
precision. Height was measured to the nearest 0.5 cm.
Body mass index was calculated as the weight in
kilograms divided by the square of height in metres.
Systolic and diastolic blood pressure values were the
means of two physician-obtained measurements 
on the left arm of the seated participant. Diabetes
was defined by either a history of fasting glucose 
≥ 126 mg/dl (7.0 mmol/l) or the use of insulin or
hypoglycaemic medications. 
Laboratory assays
Peripheral venous blood samples were taken into
tubes in the fasting state in all subjects. It was
centrifuged at 3000 rpm for 10 min for plasma
separation and immediately used to measure 
NT-proBNP and other parameters.
Fasting plasma glucose and postprandial blood
glucose concentration (glucose oxidase method,
GOX0560), serum triglycerides (GPO-PAP method,
TGP0560), high density lipoprotein cholesterol and
low density lipoprotein cholesterol (IRC method),
and serum creatinine (Sarcosine Oxidase-PAP
method, S708) of all the patients were estimated
on an automated chemistry analyser (Hitachi 7600-
020, Hitachi High-Technologies Corp, Shanghai,
China). Glycated haemoglobin was estimated by
high-pressure liquid chromatography using
a machine (HLC-723G7, Tosoh, Shanghai, China).
Plasma concentrations of NT-proBNP were
measured by the electrochemiluminescence
immunoassay “Roche Diagnostics Elecsys 2010
system” (USA), and the reference range was 
0 pg/ml to 600 pg/ml.
MetS definition
We used the definition of MetS recommended
by the Chinese Diabetes Society of the Chinese
Medical Association for the Chinese population.
Thus, individuals were defined as having MetS if
they satisfied ≥ 3 of the following 4 criteria: (1)
overweight or obese or elevated body mass index
(≥ 25.0 kg/m2), (2) high fasting plasma glucose 
(≥ 6.1 mmol/l) and/or postprandial blood glucose 
(≥ 7.8 mmol/l) and/or use of hypoglycaemic
medications, (3) high blood pressure systolic/
diastolic ≥ 140/90 mmHg or use of antihypertensive
medications, (4) high fasting triglycerides 
(≥ 1.7 mmol/l) and/or reduced high density lipopro  -
tein cholesterol (< 0.9 mmol/l in men, < 1.0 mmol/l
in women).
Echocardiography
Echocardiography examinations were performed
with a Vingmed System 5 Doppler echocardio  -
graphic unit (GE Vingmed Ultrasound, Horten,
Norway). Conventional echocardiography measure  -
ments were performed according to American
Society of Echocardiography guidelines. Left
ventricular mass (LVM) was calculated using the
Devereux formula as follows: LVM (g) = 1.04 ×
[(LVIDd + LVPWd + IVSd)3 – LVIDd3] – 13.6, where
LVIDd represents left ventricular diameter in end
diastole (cm), LVPWd represents left ventricular
posterior wall thickness in diastole (cm), and IVSd
represents interventricular septal thickness in end
diastole (cm). Left ventricular mass was corrected
for body surface area (BSA) to give LVM index
(LVMI). Left atrial diameter (LAD) and aortic root
dimension (AOD) were also measured. Left
ventricular systolic function was assessed by
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calculation of left ventricular ejection fraction (LVEF).
Diastolic function was assessed by determining the
E-to-A ratio (E/A), where E and A represent the early
and late velocities respectively.
Statistical analysis
We used natural logarithmic (Log) transfor  -
mations of peptide levels because NT-proBNP
followed approximately lognormal distributions.
Furthermore, the association between the elevation
of NT-proBNP and potential metabolic factors was
investigated by multiple linear regression analysis.
Multiple linear regression analysis was performed
to relate Log NT-proBNP to metabolic variables that
included gender, body mass index, high density
lipoprotein cholesterol, low density lipoprotein
cholesterol, systolic blood pressure, diastolic blood
pressure, fasting plasma glucose, and postprandial
blood glucose. This model also included age, serum
creatinine, AOD, LAD, LVMI, LVEF and E/A. 
Next, considering differences of NT-proBNP levels
between MetS and non-MetS groups with dis  -
turbance of the possible confounding variables, we
performed covariance analysis with adjustment for
age, gender, serum creatinine, LAD, AOD, LVMI and
LVEF which have been identified by multiple
regression analysis.
In order to better investigate the association of
NT-proBNP and the components of MetS, we
compared NT-proBNP levels of different subgroups
by covariance analysis. 
Results were analysed using the Statistical
Package for Social Sciences for Windows ver. 13.0
(SPSS, Chicago, IL, USA). Continuous variables were
expressed as mean ± SD or median (range) values.
Tests were two-sided and a p-value of < 0.05 was
considered significant.
Results
Characteristics of the study sample (n = 469) are
shown in Table I. There are 124 males and 106
females (mean age, 65.2 ±12.0 years) in the MetS
group and 142 males and 97 females (mean age,
66.0 ±12.6 years) in the non-MetS group. As
expected, body mass index, systolic blood pressure,
diastolic blood pressure, fasting blood glucose,
postprandial blood glucose, and lipid and lipoprotein
profile were significantly different between the
MetS group and the non-MetS group (p < 0.001).
Hypertension and diabetes were more prevalent in
the patients with MetS (p < 0.001). 
NT-proBNP and metabolic factors
Results of multiple linear regression models
relating Log NT-proBNP with metabolic risk factors
are shown in Table II. In all cases, a negative
association was observed between plasma 
NT-proBNP levels and body mass index (p = 0.016),
as previously described. Additionally, NT-proBNP
levels were inversely associated with diastolic blood
pressure (p = 0.015), fasting blood glucose 
(p = 0.046), triglycerides (p = 0.009), low density
lipoprotein cholesterol (p = 0.036), and LVEF 
(p ≤ 0.001). NT-proBNP was positively associated
with age (p  < 0.001), systolic blood pressure 
(p = 0.004), high density lipoprotein cholesterol 
(p = 0.013) and LVMI (p < 0.001). Plasma NT-proBNP
was negatively associated with systolic blood
pressure (p = 0.001) and fasting blood glucose 
(p = 0.015) in women but not in men. However, the
association for triglycerides (p = 0.002) and high
density lipoprotein cholesterol (p = 0.014) was
significant in men but not in women.
Log NT-proBNP levels in patients with MetS
and without MetS
The differences between the two groups of
patients in terms of their NT-proBNP levels are
displayed in Figure 1 and Table III. Plasma levels of
log NT-proBNP are lower in all participants with
MetS after adjustment for age, gender (for total
patients), serum creatinine, LAD, AOD, LVMI, and
LVEF (p = 0.001). Similarly, the decrease of 
NT-proBNP levels in patients with MetS remained
significant for men (p = 0.038) and for women 
(p = 0.022) after the same adjustment for age, and
clinical and echocardiographic characteristics.
Log NT-proBNP levels in patients of MetS
subgroups and non-MetS
Next, we divided the subjects with MetS into
subgroups according to their body mass index,
systolic blood pressure, diastolic blood pressure,
fasting blood glucose, triglycerides or high density
lipoprotein cholesterol. In men, the cut points are
25.0 kg/m2, 140 mmHg, 90 mmHg, 6.1 mmol/l, 
1.7 mmol/l or 0.9 mmol/l respectively. In women,
the cut points are similar to those of men except
that high density lipoprotein cholesterol is 
1.0 mmol/l. Covariance analyses were conducted
and adjusted for age, gender (for total patients),
serum creatinine, LAD, AOD, LVMI, and LVEF. In
addition, for example, accounting for the other MetS
components, such as dyslipidaemia, hyperglycaemia
and elevated blood pressure, may influence
comparison of log NT-proBNP levels between MetS
subgroups stratified by BMI and the non-MetS
group. So here the analyses of covariance were also
adjusted for the other MetS components except for
the categorical exposure variable (like BMI in the
above-mentioned example). The MetS components
above referred to body mass index, triglycerides,
high density lipoprotein cholesterol, low density
lipoprotein cholesterol, fasting blood glucose,250 Arch Med Sci 2, April / 2011
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Parameters MetS(+) n = 230 MetS(–) n = 239 Value of p
Sex, no., male/female 124/106 142/97
Age [year] 65.2 ±12.0 66.0 ±12.6 0.689
Smoking [%] 42 43 0.624
Hypertension [%] 53 11 < 0.001
Diabetes mellitus [%] 72 30 < 0.001
Body mass index [kg/m2] 27.0 ±4.5 23.3 ±4.2 < 0.001
FBG [mmol/l] 6.6 ±1.2 5.2 ±1.0 < 0.001
PBG [mmol/l] 9.3 ±3.0 7.3 ±2.8 < 0.001
Glycated haemoglobin [%] 6.8 ±0.8 5.8 ±0.7 < 0.001
Systolic blood pressure [mmHg] 144 (85) 130 (75) < 0.001
Diastolic blood pressure [mmHg] 89 (45) 77 (35) < 0.001
LDL cholesterol [mmol/l] 2.61 ±0.8 2.59 ±0.8 0.301
HDL cholesterol [mmol/l] 0.9 ±0.2 1.2 ±0.3 < 0.001
Triglycerides [mmol/l] 2.2 ±1.3 1.3 ±0.6 < 0.001
Serum creatinine [μmol/l] 79.5 ±25.1 79.3 ±22.7 0.175
LAD [mm] 40.0 ±7.1 38.2 ±5.9 0.238
AOD [mm] 33.0 ±3.4 33.0 ±4.5 0.642
LVM [g] 228.2 ±64.1 195.5 ±61.5 < 0.001
LVMI [g/m2] 127.3 ±31.9 119.1 ±40.5 0.023
EF [%] 62.7 ±11.7 64.5 ±9.5 0.091
E/A ratio 1.3 ±0.2 1.4 ±0.2 0.689
Medication [%]
Calcium antagonists 25.3 23.2 0.331
β-blockers 50.8 49.6 0.782
ACE inhibitors 35.4 33.1 0.534
FBG – fasting blood glucose, PBG – postprandial blood glucose, HDL cholesterol – high density lipoprotein cholesterol, LDL cholesterol – low
density lipoprotein cholesterol, LAD – left atrial diameter, AOD – aortic root dimension, EF – ejection fraction, E – transmitral early diastolic velocity,
A – transmitral late diastolic velocity, E/A – ratio of transmitral early (E) and late (A) diastolic velocities, IVS – interventricular septum, 
PW – posterior wall, LVM – left ventricular mass, LVMI – left ventricular mass index, values are mean ± SD when appropriate
Table I. Clinical characteristics of the study participants with and without MetS
Independent variables Total Men Women
β p β p β p
Age 0.337 < 0.001 0.342 < 0.001 0.387 < 0.001
Gender 0.221 0.004
Body mass index –0.173 0.007 –0.252 0.003 –0.223 0.018
Systolic blood pressure 0.217 0.004 0.114 0.225 0.372 0.001
Diastolic blood pressure –0.179 0.015 –0.186 0.034 –0.397 0.007
Fasting blood glucose –0.150 0.046 –0.176 0.093 –0.276 0.015
Triglycerides –0.265 0.009 –0.351 0.002 0.204 0.285
HDL cholesterol 0.240 0.013 0.317 0.014 0.014 0.922
LDL cholesterol –0.423 0.036 –0.456 0.170 0.102 0.715
LVMI 0.315 < 0.001 0.292 0.001 0.452 < 0.001
LVEF –0.377 < 0.001 –0.446 < 0.001 –0.372 < 0.001
FBG – fasting blood glucose, HDL cholesterol – high density lipoprotein cholesterol, LDL cholesterol – low density lipoprotein cholesterol, 
LVMI – left ventricular mass index, LVEF – left ventricular ejection fraction
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systolic blood pressure and diastolic blood pressure
when internalized as covariates. 
The differences between patients of MetS
subgroups and non-MetS in terms of their 
NT-proBNP levels are displayed in Figure 2 and
Tables IV-VIII. For all subjects totally, Log NT-proBNP
concentrations were lower in MetS subjects with
dyslipidaemia, hyperglycaemia, elevated body mass
index and diastolic blood pressure than those
without MetS (p  < 0.05), but did not reach
significance in MetS subjects with normal blood fat,
glucose, body mass index, systolic blood pressure
and diastolic blood pressure compared to those
without MetS (p = NS). However, Log NT-proBNP
levels were higher in MetS patients with elevated
systolic blood pressure than non-MetS patients 
(p < 0.05). Similar findings were obtained in men
and women except for women with elevated body
mass index.
Discussion
N-terminal pro-B-type natriuretic peptide 
(NT-proBNP), the inactive amino terminal fragment,
and the biologically active form of B-type natriuretic
peptide (BNP), are cleavage products of the
precursor pre-proBNP which is synthesized by
ventricular myocytes in response to physiological
signals such as stretching of the ventricular wall or
changes in systemic blood pressure, sodium levels
or extracellular volume. B-type natriuretic peptide
is metabolized by specific natriuretic peptide
receptors found in the kidney, lung, liver, and along
the vascular endothelium, while NT-proBNP is
mainly cleared by the kidneys. It has recently been
recognized as a new and useful biochemical marker
for both diagnosis and ruling out of congestive
heart failure (CHF) [1]. For the present, assessment
of plasma NT-proBNP concentration is of potential
value for risk of death and cardiovascular
complications in the general population and may
be useful for detection of a symptomatic left
ventricular systolic dysfunction and systolic
dysfunction in the general population [7, 8]. Recent
clinical trials have also shown that NT-proBNP is
elevated in patients with acute coronary syndrome
(ACS) and exercise training in patients after
myocardial infarction could decrease plasma 
NT-proBNP levels [9, 10]. Baghdady et al. observed
an increase of NT-proBNP levels in ventricular septal
defect with cardiac decompensation, and it is
correlated with clinical score and echocardiography
parameters [11].
NT-proBNP and metabolic syndrome
An inverse relationship between BNP and MetS
has been described previously in the Framingham
Heart Study [2]. In addition, levels of NT-proBNP
have also been detected to be significantly lower
in MetS [6]. Consistent with the above-mentioned
finding, differences of NT-proBNP plasma concen  -
trations were established between MetS and non-
MetS in our study by covariance analysis after
adjustment for age, gender (for total patients),
serum creatinine, LAD, AOD, LVMI, and LVEF. On the
other hand, to the best of our knowledge, ours is
the first investigation to demonstrate that plasma
NT-proBNP is lower in patients with MetS defined
by the Chinese Diabetes Society of the Chinese
Medical Association. 
NT-proBNP, body mass index and blood lipid
Consistent with prior experimental observations
[12], we found that there is a strong relationship
between serum NT-proBNP and plasma triglycerides,
high density lipoprotein cholesterol, and low density
lipoprotein cholesterol levels, suggesting a strong
relationship between NT-proBNP and lipid meta  -
bolism. An inverse relationship between serum 
NT-proBNP and cholesterol has been described
previously and has been hypothesized to be
a potential link impairing the natural blood pressure
regulation [6]. Our data support to some degree this
hypothesis because of the inverse relationship
between low density lipoprotein cholesterol and
NT-proBNP . Log NT-proBNP levels were also found
to be significantly lower in patients of MetS
subgroups stratified by plasma triglycerides and
high density lipoprotein cholesterol compared to
those without MetS, suggesting a negative
association between lower NT-proBNP concen  tra  -
tion and hyper  lipidaemia.
We also found that there is a strong relationship
between serum NT-proBNP and body mass index.
An inverse relationship between serum BNP and
body mass index has been described recently [13],
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Figure 1. Adjusted log NT-proBNP levels in patients
with Mets and without Mets
MetS – metabolic syndrome, NT-proBNP – N-terminal pro-B-
type natriuretic peptide. Covariance analysis between groups
was carried out. Levels were obtained by log transformation
of NT-proBNP levels adjusted for age, gender, serum
creatinine, LAD, AOD, LVMI, and LVEF. Data are presented as
mean ± SD
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Figure 2. Adjusted log NT-proBNP levels in subgroups of MetS and patients without MetS
MetS – metabolic syndrome, NT-proBNP – N-terminal pro-B-type natriuretic peptide. Levels were obtained by log transformation of
NT-proBNP levels. Covariance analysis between groups was carried out and adjusted for age, serum creatinine, left atrial diameter, left
ventricular mass, left ventricular ejection fraction and the other MetS covariates. Datas are presented as mean ± SD; NS – no significant
Total Men Women
n Log NT-proBNP n Log NT-proBNP n Log NT-proBNP
MetS(+) 230 2.173 ±0.044 124 2.110 ±0.056 106 2.022 ±0.074
MetS(–) 239 2.367 ±0.035 142 2.261 ±0.045 97 2.232 ±0.055
Value of p 0.001 0.038 0.022
MetS – metabolic syndrome, NT-proBNP – N-terminal pro-B-type natriuretic peptide. Covariance analysis between groups was carried out. Levels
were obtained by log transformation of NT-proBNP levels adjusted for age, gender, serum creatinine, LAD, AOD, LVMI, and LVEF. Data are presented
as mean ± SD
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Total Men Women
n Log NT-proBNP n Log NT-proBNP n Log NT-proBNP
MetS(–) 239 2.391 ±0.044 142 2.289 ±0.056 97 2.476 ±0.063
MetS(+) 230 124 106
Non-dyslipidaemia 110 2.275 ±0.084 51 2.145 ±0.093 59 2.329 ±0.135
(p = 0.243) (p = 0.213) (p = 0.342)
Dyslipidaemia 120 2.133 ±0.059 73 2.044 ±0.082 47 2.213 ±0.084
(p = 0.002) (p = 0.026) (p = 0.020)
MetS – metabolic syndrome, NT-proBNP – N-terminal pro-B-type natriuretic peptide. Covariance analysis between groups was carried out. Levels
were obtained by log transformation of NT-proBNP levels adjusted for age, gender, serum creatinine, LAD, AOD, LVMI, and LVEF. Data are presented
as mean ± SD
Table IV. Adjusted log NT-proBNP levels in blood lipid subgroups of MetS and patients without MetS
Total Men Women
n Log NT-proBNP n Log NT-proBNP n Log NT-proBNP
MetS(–) 239 2.317 ±0.068 142 2.317 ±0.087 97 2.388 ±0.090
MetS(+) 230 124 106
BMI < 25 kg/m2 89 2.182 ±0.099 46 2.130 ±0.100 43 2.126 ±0.190
(p = 0.257) (p = 0.147) (p = 0.214)
BMI ≥ 25 kg/m2 141 1.916 ±0.108 78 1.904 ±0.175 63 2.074 ±0.127
(p = 0.002) (p = 0.040) (p = 0.057)
MetS – metabolic syndrome, NT-proBNP – N-terminal pro-B-type natriuretic peptide. Covariance analysis between groups was carried out. Levels
were obtained by log transformation of NT-proBNP levels adjusted for age, gender, serum creatinine, LAD, AOD, LVMI, and LVEF. Data are presented
as mean ± SD
Table V. Adjusted log NT-proBNP levels in BMI subgroups of MetS and patients without MetS
Total Men Women
n Log NT-proBNP n Log NT-proBNP n Log NT-proBNP
MetS(–) 239 2.325 ±0.046 142 2.323 ±0.055 97 2.399 ±0.054
MetS(+) 230 124 106
FPG < 6.1 mmol/l 105 2.296 ±0.100 55 2.218 ±0.088 50 2.328 ±0.119
(p = 0.795) (p = 0.328) (p = 0.602)
FPG ≥ 6.1 mmol/l 125 2.068 ±0.089 69 2.021 ±0.104 56 2.165 ±0.085
(p = 0.012) (p = 0.026) (p = 0.031)
MetS – metabolic syndrome, NT-proBNP – N-terminal pro-B-type natriuretic peptide. Covariance analysis between groups was carried out. Levels
were obtained by log transformation of NT-proBNP levels adjusted for age, gender, serum creatinine, LAD, AOD, LVMI, and LVEF. Data are presented
as mean ± SD
Table VI. Adjusted log NT-proBNP levels in FPG subgroups of MetS and patients without MetS
Total Men Women
n Log NT-proBNP n Log NT-proBNP n Log NT-proBNP
MetS(–) 239 2.258 ±0.071 142 2.214 ±0.088 97 2.445 ±0.077
MetS(+) 230 124 106
SBP < 140 mmHg 109 1.919 ±0.147 56 1.795 ±0.188 53 1.991 ±0.124
(p = 0.032) (p = 0.045) (p = 0.006)
SBP ≥ 140 mmHg 121 2.416 ±0.106 68 2.316 ±0.150 53 2.375 ±0.120
(p = 0.212) (p = 0.560) (p = 0.643)
MetS – metabolic syndrome, NT-proBNP – N-terminal pro-B-type natriuretic peptide. Covariance analysis between groups was carried out. Levels
were obtained by log transformation of NT-proBNP levels adjusted for age, gender, serum creatinine, LAD, AOD, LVMI, and LVEF. Data are presented
as mean ± SD
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which is also supported to some degree by our
data. This is also supported by previous obser  -
vations that obese subjects are more sensitive to
sodium load on account of a reduced effect of atrial
natriuretic peptide, partly attributable to increased
removal of natriuretic peptide from the circulation
by adipocytes through abundant natriuretic peptide
clearance receptors in adipose tissue of obese
people [14]. NT-proBNP may also relate to this, but
the importance of the natriuretic clearance receptor
for clearance of NT-proBNP is unknown [15].
Alternatively, NT-proBNP may, through lipolytic and
lipomobilizing effects, change the metabolic state
as demonstrated for atrial natriuretic peptide [16]
and reduce the incidence of overweight and obesity.
An association between natriuretic peptides 
and levels of the insulin-sensitizing hormone
adiponectin has been reported, with low levels of
BNP associated with low levels of adiponectin
despite adjustment for body mass index [17].
Natriuretic peptides also stimulate lipolysis and
release of triacylglycerols from adipose tissue [18].
Reduced natriuretic peptide signalling could have
detrimental effects via the promotion of lipid
accumulation in adipose tissue and skeletal muscle. 
NT-proBNP and blood glucose
An inverse relationship between plasma 
NT-proBNP levels and fasting blood glucose was
found in our study. Log NT-proBNP levels were also
found to be significantly lower in patients of MetS
subgroups stratified by fasting blood glucose
compared to non-MetS subjects. Some expe  -
rimental observations suggest that low natriuretic
peptide levels could predispose to insulin resistance.
Reduced natriuretic peptide activity leads to greater
activation of the renin-angiotensin system [19].
Activation of the renin-angiotensin system pro  -
motes the development of insulin resistance via
multiple mechanisms [20], including inhibition of
intracellular insulin signalling, enhanced oxidative
stress, inflammation, reduced adipocyte differen  -
tiation, and decreased perfusion to the skeletal
muscle and pancreas.
Natriuretic peptides and blood pressure
Previous studies have reported a positive
association between plasma natriuretic peptide
levels and systolic blood pressure [21]. In conformity
with these data, we also found that low NT-proBNP
levels were associated with almost all component
of the metabolic syndrome except elevated systolic
blood pressure, which was associated with higher
plasma NT-proBNP levels, indicating the haemo  -
dynamic influence of blood pressure on natriuretic
peptide synthesis. The observation that plasma 
NT-proBNP levels relate differently to systolic blood
pressure than to other metabolic components
suggests that blood pressure segregates separately
from other MetS components [22]. In the Insulin
Resistance Atherosclerosis Study, Hanley et al. [22]
used principal factor analysis to identify 2 "factors".
One is a metabolic factor, consisting of body mass
index, glycaemic measures, triglycerides, and high
density lipoprotein cholesterol; the other is a blood
pressure factor, comprising systolic and diastolic
blood pressure. HOMA-IR and fasting insulin
correlated with the metabolic factor but not with
the blood pressure factor. These data suggest 
that blood pressure may have a different patho  -
physiological mechanism from other metabolic
components, which may help to interpret the
different association between systolic blood
pressure and NT-proBNP from others. There is an
inverse correlation between plasma NT-proBNP
levels and diastolic blood pressure, which may
reflect the influence of pulse pressure [6]. Increased
pulse pressure is often accompanied by lower
diastolic blood pressure, particularly in older
individuals. 
NT-proBNP and other risk factors
The association between left ventricular
hypertrophy and plasma levels of NT-proBNP is
consistent. Some studies have found an association
between NT-proBNP levels and left ventricular
hypertrophy, whereas others have not [8]. In the
present study we found there was an independent
Total Men Women
n Log NT-proBNP n Log NT-proBNP n Log NT-proBNP
MetS(–) 239 2.273 ±0.045 142 2.200 ±0.058 97 2.439 ±0.073
MetS(+) 230 124 106
DBP < 90 mmHg 107 2.250 ±0.091 59 2.146 ±0.132 48 2.420 ±0.123
(p = 0.824) (p = 0.715) (p = 0.906)
DBP ≥ 90 mmHg 123 2.001 ±0.059 65 1.974 ±0.078 58 2.024 ±0.092
(p < 0.001) (p = 0.028) (p = 0.002)
MetS – metabolic syndrome, NT-proBNP – N-terminal pro-B-type natriuretic peptide. Covariance analysis between groups was carried out. Levels
were obtained by log transformation of NT-proBNP levels adjusted for age, gender, serum creatinine, LAD, AOD, LVMI, and LVEF. Data are presented
as mean ± SD
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association between left ventricular mass index and
NT-proBNP levels in subjects.
Age has been shown to influence circulating
natriuretic peptide levels, and the magnitude of the
effects and potential importance in the inter  -
pretation of NT-proBNP remain unclear [23].
A possible explanation for increased NT-proBNP
levels with age may be increased age-related
fibrosis, diastolic dysfunction and reduced renal
clearance [24]. In this study we also found that 
NT-proBNP levels were positively related to age in
all subjects.
Comparison with previous studies
An inverse association between plasma
natriuretic peptide levels and obesity has previously
been described in the Framingham [2] and other
studies [13, 25]. However, few studies have
investigated the relations between NT-proBNP levels
and metabolic components, especially in MetS
subjects diagnosed according to recommendations
of the Chinese Diabetes Society. Inconsistent
associations have been reported between plasma
natriuretic peptides and glycaemic status [5] or
plasma lipids [4]. In the population-based Danish
cohort of Olsen et al. [6], plasma NT-proBNP levels
were inversely associated with serum total
cholesterol, serum triglycerides and plasma glucose.
The present study differs from those findings by
the use of covariance analyses and the ability to
adjust for differences in age, gender, renal function
with serum creatinine, LAD, AOD, LVMI, and LVEF.
In addition, as gender is an independent factor
influencing NT-proBNP levels, we divided all
subjects into male and female groups. For men,
fasting blood glucose was not an independent
predictor of NT-proBNP, while for women NT-
proBNP levels were not independently correlated
with blood lipid. Notwithstanding the above, the
similarity in study findings provides convincing
evidence of an association between the natriuretic
peptide and metabolic components. 
Several limitations of the study deserve
comment. First, the study results indicated that 
NT-proBNP is different in MetS subjects from non-
MetS. The fact that NT-proBNP was related to
metabolic components independently of age and
clinical and echocardiographic characteristics
indicates that NT-proBNP is a superior marker of
metabolic syndrome and therefore suitable to
detect subclinical MetS before it develops into
clinical disease. However, the positive or negative
relationship between NT-proBNP and metabolic
components may be a problem when defining 
cut-off values for varying levels of obesity,
dyslipidaemia, or hyperglycaemia. Here subgroups
are established according to the Chinese criteria.
Next, further studies are required to investigate 
NT-proBNP levels in MetS subgroups by other
traditional cut-off levels in patients. Second, the
multiple regression models explained only
a moderate influence of potential risk factors on
NT-proBNP levels. Other environmental factors may
contribute to the unexplained variation. Finally, it
is important to mention that our study concerned
Chinese individuals and our findings may not be
relevant to those of other countries.
The diagnostic value of plasma natriuretic
peptide measurements has been demonstrated in
a variety of settings. The range of factors that may
influence the biomarker needs to be understood
for interpretation of the results. Previous studies
have shown the use of lower natriuretic peptide cut
points for diagnosing heart failure in obese
individuals [25]. Our data raise the possibility that
other metabolic components should be taken into
account when plasma natriuretic peptide 
(NT-proBNP) measurements are interpreted. But
whether diagnostic thresholds should be altered in
individuals with the metabolic syndrome is
unknown and needs further investigation in
prospective studies. In addition to that, because
natriuretic peptides play an important role in the
counter-regulatory response to volume and
pressure overload, it is possible that lower
natriuretic peptide levels contribute to the
susceptibility of individuals with the metabolic
syndrome to hypertension and left ventricular
hypertrophy.
In conclusion, plasma NT-proBNP levels were
lower in patients with MetS, especially in MetS
patients with dyslipidaemia, elevated body mass
index, fasting blood glucose and diastolic blood
pressure. Our data raise the possibility that reduced
plasma NT-proBNP levels may be a marker for MetS,
which might possess significant clinical and
pathophysiological implications. More prospective
studies are needed regarding the relations of lower
NT-proBNP levels and sodium, insulin resistance,
and the impact of reduced natriuretic peptide levels
on cardiovascular events in MetS.
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